Bevasiranib trial for wet-AMD discontinued

OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).

OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).

An analysis of the preliminary data conducted by an independent data monitoring committee demonstrated that the trial was unlikely to meet its primary end point (improvement in visual acuity), although bevasiranib used adjunctively with ranibizumab (Lucentis, Genentech) did show activity in this disease state.

No systemic safety issues were identified in the trial.